# OnCo record nct04821622 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04821622/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04821622", "NCT04821622" ;
  schema:name "Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC"@en ;
  schema:alternateName "TALAPRO-3"@en ;
  schema:description "A phase 3 trial of Talazoparib and Enzalutamide in prostate cancer, run by Pfizer, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04821622/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04821622> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2021-05-12" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mhspc/> ;
  onco:technologies <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/drugs/enzalutamide/> ;
  onco:companies <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/astellas/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct04821622-n-engl-j-med-2026/> .